Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (1270)	9/7/2000 9:16:21 AM
From: scott_jiminez	Respond to of 4474

Well they did this biz.yahoo.com in June and, together with the HMR buyout of the Genomics Core, and a milestone payment from same, over the past ~10 months, my impression is their cash position is quite healthy. I have no idea how this compares to recent financing arrangements. It's not a thousand million dollars but it may be perfectly appropriate for a company Ariad's size. However, from what I recall, Berger has stated the company's cash position will allow for generally smooth sailing through at least 2002. This statement was made following the HMR buyout ergo prior to the additional financing from Wellington. I cannot not claim to gauge management's ambition. The fact they made the Wellington arrangement despite the fact they were sitting pretty with the HMR cash may provide some insight.